Abstract: Objective To investigate the clinical efficacy of azithromycin and propoxyguanosine aerosol inhalation in children with bronchopneumonia and the effect on the level of inflammatory factors. Methods A total of 84 children with bronchopneumonia admitted to the pediatrics department of Yantai Beihai Hospital from August 2021 to August 2022 were selected as the subjects of this study. The children were randomly divided into control group and study group according to coin toss method. Among them, 42 cases in the control group received atomized inhalation therapy of propioguanosine, and 42 cases in the study group. Azithromycin combined with propoxyguanosine atomized inhalation therapy, the duration of clinical symptom disappearance, length of hospital stay, total response rate, levels of inflammatory factors (TNF-α, interleukin-1β), lung function [(forced vital capacity (FVC), forced expiratory volume in the first second (FEV₁), and ratio of forced expiratory volume in the first second to forced vital capacity (FEV₁/FVC) were compared between the two groups )]. Results The duration of cough relief, fever disappearance, shortness of breath disappearance and hospital stay in the study group were shorter than those in the control group (P<0.05). The total effective rate of the study group was higher than that of the control group (P<0.05). The levels of TNF-α and IL-1β in the two groups before treatment were compared (P>0.05), and the levels of TNF-α and IL-1β in the two groups were decreased after treatment, and the levels in the study group were lower than those in the control group (P<0.05). The levels of FVC, FEV₁ and FEV₁/FVC in both groups before treatment (P>0.05), and the levels of FVC, FEV₁ and FEV₁/FVC in both groups were improved after treatment, and the study group was higher than the control group (P<0.05). Conclusion The combined treatment of azithromycin and propoxyguanyside aerosol inhalation in children with bronchopneumonia has definite curative effect, can significantly shorten the improvement time of clinical symptoms, reduce the inflammatory reaction of the body, improve lung function, and is worthy of clinical use.

Key words: azithromycin, propoxyguanosine, bronchial pneumonia in children, efficacy, inflammatory factor